Drug Profile
Piflufolastat F18 - Curium Pharma/Progenics Pharmaceuticals
Alternative Names: 18FDCFPyL (PyL-PSMA) PET/CT; [18F]-DCFPyL; DCFPyL-18F; Fluorine-18 DCFPyL; Fluorine-18 piflufolastat; Piflufolastat F 18 injection; PyL; PYLARIFY; PYLCLARILatest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator Johns Hopkins University School of Medicine
- Developer Curium Pharma; Progenics Pharmaceuticals
- Class Amides; Carboxylic acids; Fluorinated hydrocarbons; Imaging agents; Pyridines; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules; Urea compounds
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Prostate cancer
Most Recent Events
- 09 Apr 2024 Launched for Prostate cancer (Diagnosis) in Netherlands (IV)
- 15 Feb 2024 Progenics Pharmaceuticals terminates a phase II trial in Prostate cancer (Diagnosis) in USA (IV), as the intervention became FDA-approved (NCT04727736)
- 03 Feb 2024 Launched for Prostate cancer (Diagnosis) in Italy (IV)